Many gray-market wellness peptides are drugs that originated inside the pharmaceutical pipeline and were abandoned due to inadequate efficacy, safety concerns, or poor pharmacokinetics.
Snapshot · The Peter Attia Drive
Many gray-market wellness peptides are drugs that originated inside the pharmaceutical pipeline and were abandoned due to inadequate efficacy, safety concerns, or poor pharmacokinetics.
Where this was said
At 44:30 · chapter starts 43:00
The episode's most structurally contrarian argument arrives here: the popular claim that pharmaceutical companies ignore effective natural peptides because they can't be patented. Peter grants the kernel of truth — you can't patent a product of nature in raw form — but then systematically dismantles the larger claim. Companies routinely patent modified analogs, new salts, conjugates, delivery systems, manufacturing processes, and dosing regimens. Rapamycin, metformin, and the statins all began as natural molecules and became commercially patentable. Even BPC-157 has existing patents on its salts and production methods. More powerfully, Peter notes that if gray-market peptides truly worked as advertised, the same pharmaceutical industry currently racing to develop GLP-1 variants would be racing to develop them too. [1] — Peter Attia "You can't patent a product of nature, but companies routinely patent modified analogs, salts, delivery systems, and dosing regimens. Rapamy…" 43:45 The conspicuous absence of that race is telling. Many gray-market wellness peptides are in fact drugs that originated inside the pharmaceutical pipeline and were abandoned — not suppressed, but abandoned — due to inadequate efficacy, safety concerns, poor pharmacokinetics, or competition from better drugs. The CJC-1295 / tesamorelin comparison makes this concrete: same biology, developed simultaneously, but tesamorelin's superior data got it over the finish line while CJC-1295 was dropped. The gray market, Peter concludes, is pharma's salvage yard.
CJC-1295 and tesamorelin share the same underlying biology and were developed around the same time, but CJC-1295 was abandoned at phase 2 while tesamorelin reached full FDA approval — because the data were better.
You can't patent a product of nature, but companies routinely patent modified analogs, salts, delivery systems, and dosing regimens. Rapamycin, metformin, and the statins all started as natural molecules and became patentable. If gray-market peptides delivered on their claims, the same industry racing to develop GLP-1 variants would already be racing to develop them.
CJC-1295 is actually named after ConjuChem, the pharmaceutical company that developed and then abandoned it — a fact that illustrates how gray-market peptides often originate inside industry pipelines.
Making the first hour of your day high-cortisol and the last hour low-cortisol is described as the single most impactful daily habit for mood, focus, alertness, stress resilience, and sleep quality.
A Washington University in St. Louis study found that a great night's sleep produces attention-improvement effects effectively equal to Ritalin.
In the 4 to 6 hours after exercise, dopamine and norepinephrine are elevated, making you more alert and better able to focus — unless you've exercised to exhaustion.
The physiological sigh — two big inhales followed by a full exhale — was discovered by physiologists in the 1930s and is the fastest way to reduce autonomic arousal.
Doing just 10 deliberate exhales throughout the day can significantly elevate heart rate variability by the evening, by repeatedly activating the vagal sinoatrial node pathway.
For nicotine to have a genuine cognitive-enhancing effect rather than merely rescuing withdrawal deficit, Huberman recommends using it only once or twice per week at 3–6 mg.
Because vaping can be done anywhere and is more palatable, people consume far more nicotine via vaping than they ever did smoking, potentially making vaping more dangerous in aggregate despite being safer per puff.
Huberman reported that two injections of approximately 100–200 micrograms of BPC-157 eliminated persistent shoulder pain that had resisted months of other interventions.
Huberman reported that on nights he used the peptide pinealon, he achieved 2.5 to 3 hours of REM sleep inside 6 hours — an unusually high proportion normally only found in the final hours of longer sleep.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.